(Q34422784)

2 August 2017

1 reference

title

Insulin resistance and beta-cell function--a clinical perspective (English)

1 reference

2 August 2017

1 reference

1 reference

Matthews DR

1

1 reference

PubMed ID

11685826

2 August 2017

language of work or name

1 reference

1 August 2001

1 reference

Diabetes, Obesity and Metabolism

2 August 2017

1 reference

2 August 2017

3 Suppl 1

1 reference

2 August 2017

S28-33

1 reference

Pancreatic beta-cell dysfunction as the primary genetic lesion in NIDDM. Evidence from studies in normal glucose-tolerant individuals with a first-degree NIDDM relative.

2 August 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00029.X

Insulin resistance: the fundamental trigger of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00029.X

Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00029.X

The global epidemiology of non-insulin-dependent diabetes mellitus and the metabolic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00029.X

The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00029.X

Hyperglycaemic progression in subjects with impaired glucose tolerance: association with decline in beta cell function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00029.X

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00029.X

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00029.X

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00029.X

Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00029.X

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00029.X

Correct homeostasis model assessment (HOMA) evaluation uses the computer program

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00029.X

Natural history of pancreatic islet B-cell function in type 2 diabetes mellitus studied over six years by homeostasis model assessment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00029.X

Islet amyloid: a long-recognized but underappreciated pathological feature of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00029.X

Protection against lipoapoptosis of beta cells through leptin-dependent maintenance of Bcl-2 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00029.X

Rosiglitazone monotherapy is effective in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00029.X

Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00029.X

Thiazolidinediones in the treatment of insulin resistance and type II diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00029.X

10.1046/J.1463-1326.2001.00029.X

21 January 2018

Identifiers

DOI

1 reference

2 August 2017

1 reference